376270.Kq
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company's capital structure is highly leveraged, with a debt-to-equity ratio of 3.86, indicating a significant reliance on debt financing. Despite holding 13.25 billion KRW in cash and equivalents, the company's liquidity position is rated as medium, likely due to the large long-term debt of 19.26 billion KRW. The current ratio of 0.56 suggests the company may struggle to meet its short-term obligations with its current assets.
Profitability metrics are severely negative, with a return on equity of -4.78 and a return on assets of -0.46, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. These figures are well below the industry norms for biotechnology and medical research firms, which typically require high R&D investment and have longer time horizons for profitability.
The company's revenue is not segmented by geographic region or product line in the available data, but the negative operating and net income figures suggest that the company is not currently generating positive returns from its operations. There is no indication of geographic diversification or segment-specific performance in the provided financial data.
The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The negative operating cash flow of 8.34 billion KRW and free cash flow of 31.11 billion KRW indicate that the company is not generating sufficient cash from operations to fund its activities or growth. The capital expenditure of 9.98 billion KRW further suggests that the company is investing in its operations, but this is not being offset by positive cash flows.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations without additional financing. The dilution risk is low, suggesting that the company is not expected to issue a significant number of new shares in the near term. However, the company's negative net income and cash flows may necessitate future financing, which could lead to dilution if equity is used.
Recent events and filings are not detailed in the provided data, but the company's financial performance suggests that it may be facing operational and financial challenges. The negative operating and net income figures, combined with the high debt levels, indicate that the company may need to take corrective actions to improve its financial position.
- The company has a highly leveraged capital structure with a debt-to-equity ratio of 3.86.
- Profitability is negative, with a return on equity of -4.78 and a return on assets of -0.46.
- The company's liquidity position is rated as medium, despite holding 13.25 billion KRW in cash and equivalents.
- The company is not generating positive cash flows from operations, with a negative operating cash flow of 8.34 billion KRW.
- The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
- "margin_outlook_rationale": "The company's margin outlook is negative due to its current operating and net losses, which indicate declining profitability.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 376270.KQ Market data — financials · 2026-05-26